Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (OTCPK:ATXI)

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire November 14, 2024

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

GlobeNewswire October 9, 2024

Avenue Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 3, 2024

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire August 13, 2024

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2024

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire June 20, 2024

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

GlobeNewswire May 16, 2024

AXTI DEADLINE ALERT: Bernstein Liebhard LLP Reminds AXT, Inc. Investors of Upcoming Deadline

ACCESS Newswire May 15, 2024

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire May 15, 2024

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

GlobeNewswire April 29, 2024

Avenue Therapeutics Announces Reverse Stock Split

GlobeNewswire April 24, 2024

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

GlobeNewswire March 25, 2024

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 18, 2024

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

GlobeNewswire March 15, 2024

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

GlobeNewswire March 11, 2024

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

GlobeNewswire February 22, 2024

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESS Newswire January 16, 2024

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

GlobeNewswire January 11, 2024

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

GlobeNewswire January 5, 2024

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

GlobeNewswire January 4, 2024